WASHINGTON, Oct. 28, 2020 /PRNewswire/ — Vanda Pharmaceuticals, Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the third quarter ended September 30, 2020.
“Vanda continued to deliver strong commercial performance in the third quarter, despite the ongoing COVID-19 pandemic, while at the same time we advanced our robust clinical development pipeline,” said Mihael H. Polymeropoulos, M.D., Vanda’s President and CEO.
Key Financial and Corporate Highlights
Third Quarter of 2020
- Total net product sales from HETLIOZ® and Fanapt® were $60.3 million in the third quarter of 2020, a 1% increase compared to $59.5 million in the third quarter of 2019.
- HETLIOZ® net product sales were $39.6 million in the third quarter of 2020, a 5% increase compared to $37.6 million in the third quarter of 2019.
- Fanapt® net product sales were $20.7 million in the third quarter of 2020, a 6% decrease compared to
Article source: https://www.biospace.com/article/releases/vanda-pharmaceuticals-reports-third-quarter-2020-financial-results/
Recent Comments